Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13626178 | 1.00 | TSHR (0.46) | TSHRG6PDPOLBMMP12ALDH1A1 | |
| SCHEMBL7181668 | 0.88 | PDE4A (0.46) | — | |
| SCHEMBL585331 | 0.84 | TSHR (0.47) | TSHRPOLBALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL837629 | 0.81 | TSHR (0.44) | TSHRPOLBALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL873038 | 0.80 | MMP12 (0.45) | TSHRG6PDPOLBMMP12ALDH1A1 | |
| SCHEMBL13074081 | 0.80 | MMP12 (0.57) | TSHRG6PDPOLBMMP12ALDH1A1 | |
| SCHEMBL2555409 | 0.79 | SIGMAR1 (0.56) | MEN1KMT2AOPRK1 | |
| SCHEMBL13189946 | 0.79 | SIGMAR1 (0.56) | MEN1KMT2AOPRK1 | |
| SCHEMBL13006663 | 0.79 | SIGMAR1 (0.56) | MEN1KMT2AOPRK1 | |
| SCHEMBL13713720 | 0.79 | ESR1 (0.50) | TSHRCYP1A2MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11199890-A | — | — | None | — | — | JP | disclosed |
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-8735048-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film using the composition and pattern forming method | FUJIFILM CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735048-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film using the composition and pattern forming method | FUJIFILM CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20120301817-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM USING THE COMPOSITION AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120301817-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM USING THE COMPOSITION AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | ANTHERA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-8048880-B2 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20100285540-A1 | Process for the preparation of (R)-Beta-Arylalanines by coupled Racemase/Aminomutase catalysis | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100204249-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | ANTHERA PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | ANTHERA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2005019221-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| JP-H11199890-A | USE OF 1-METHOXY-2-METHYL-3-PHENYLPROPANE, 1-(2-METHOXYPROPYL)-4-METHYLBENZENE AND 3-METHOXY-2,2,3-TRIMETHYL-1-PHENYLBUTANE IN PERFUME | FIRMENICH SA | 1999-07-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | TSHR 2687/4885G6PD 1203/4885POLB 756/4885 |
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLAA, PLA2G12A, PLAAT2 | TSHR 4371/4885G6PD 2094/4885POLB 3885/4885 |
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLAA, PLA2G3 | TSHR 4159/4885G6PD 3366/4885POLB 3649/4885 |
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | TSHR 3681/4885G6PD 2583/4885POLB 3013/4885 |
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | PCSK9, PCSK6, NAPRT | TSHR 3710/4885G6PD 1719/4885POLB 2372/4885 |
| US-20100204249-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | PLA2G12A, PLA2G3, PLA2G2E | TSHR 2359/4885G6PD 1386/4885POLB 2160/4885 |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | PLA2G12A, PLA2G3, PLA2G2E | TSHR 2766/4885G6PD 2268/4885POLB 2207/4885 |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | TSHR 3681/4885G6PD 2583/4885POLB 3013/4885 |
| US-20100285540-A1 | Process for the preparation of (R)-Beta-Arylalanines by coupled Racemase/Aminomutase catalysis | ARSA, RNPEP, DDC | TSHR 1679/4885G6PD 617/4885POLB 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.